Disease · EFO_0005757

vaginal inflammation

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. vaginal inflammation. Diseases, record EFO_0005757. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/EFO_0005757

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: vaginal inflammation; Open Targets
Open Targets ID: EFO_0005757; Open Targets
Other names: inflammation of vagina, vagina inflammation, vaginitis, vaginitis (disease); Open Targets
Disease Ontology: DOID:2170; Disease Ontology
MeSH: D014627; MeSH
NCI Thesaurus: C26911; NCI Thesaurus
Highest stage of its drugs: Approval, for 4 of its 13 drugs, from ATC; Open Targets

Drugs13

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
BENZYDAMINE	CHEMBL12610	Small molecule	Approval	ATC	1	0	0	Drugs and targets
FLUNOXAPROFEN	CHEMBL1614641	Small molecule	Approval	ATC	1	0	0	Drugs and targets
IBUPROFEN	CHEMBL521	Small molecule	Approval	ATC	1	0	0	Drugs and targets
NAPROXEN	CHEMBL154	Small molecule	Approval	ATC	1	0	0	Drugs and targets
CLINDAMYCIN	CHEMBL1753	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
FENTICONAZOLE	CHEMBL1651990	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
FLUOCINOLONE ACETONIDE	CHEMBL989	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
LIDOCAINE	CHEMBL79	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
METRONIDAZOLE	CHEMBL137	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
NYSTATIN	CHEMBL5465559		Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets

1 to 10 of 13

See all 13 drugs

Targets13

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
PTGS1	Cyclooxygenase	3	Cyclooxygenase inhibitor	Approval	https://conductscience.org/library/genes/5742	Drugs and targets
PTGS2	Cyclooxygenase	3	Cyclooxygenase inhibitor	Approval	https://conductscience.org/library/genes/5743	Drugs and targets
NR3C1	Glucocorticoid receptor	1	Glucocorticoid receptor agonist	Phase 3	https://conductscience.org/library/genes/2908	Drugs and targets
SCN10A	Sodium channel alpha subunit	1	Sodium channel alpha subunit blocker	Phase 3	https://conductscience.org/library/genes/6336	Drugs and targets
SCN11A	Sodium channel alpha subunit	1	Sodium channel alpha subunit blocker	Phase 3	https://conductscience.org/library/genes/11280	Drugs and targets
SCN1A	Sodium channel alpha subunit	1	Sodium channel alpha subunit blocker	Phase 3	https://conductscience.org/library/genes/6323	Drugs and targets
SCN2A	Sodium channel alpha subunit	1	Sodium channel alpha subunit blocker	Phase 3	https://conductscience.org/library/genes/6326	Drugs and targets
SCN3A	Sodium channel alpha subunit	1	Sodium channel alpha subunit blocker	Phase 3	https://conductscience.org/library/genes/6328	Drugs and targets
SCN4A	Sodium channel alpha subunit	1	Sodium channel alpha subunit blocker	Phase 3	https://conductscience.org/library/genes/6329	Drugs and targets
SCN5A	Sodium channel alpha subunit	1	Sodium channel alpha subunit blocker	Phase 3	https://conductscience.org/library/genes/6331	Drugs and targets

1 to 10 of 13

See all 13 targets

Trials2

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT01867164	A Study to Compare Efficacy and Safety of an Ovule Containing Terconazole, Clindamycin and Fluocinolone Versus an Ovule Containing Metronidazole, Nystatin and Fluocinolone in the Treatment of Secondary Vulvar/ or Vaginal Symptoms of Infectious Vaginitis/ and Infectious Vaginosis	Phase 3	160	2013-12-24	Vaginitis, Infectious Vaginosis	CLINDAMYCIN, FLUOCINOLONE ACETONIDE, METRONIDAZOLE, NYSTATIN, TERCONAZOLE	Its record names the disease	ClinicalTrials.gov
NCT06056947	Evaluation of Efficacy and Safety of Two New Formulations Compared to Gynomax® XL Ovule	Phase 3	577		Trichomonal Vaginitis, Bacterial Vaginosis, Candidal Vulvovaginitis, Mixed Vaginal Infections	FENTICONAZOLE, LIDOCAINE, TINIDAZOLE	Open Targets' reading of its record	ClinicalTrials.gov

Comparisons in its trials1

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial
Gynoclin V (Terconazole+Clindamycin+Fluocinolone Acetonide) vs Vagitrol V (Metronidazole+Fluocinolone Acetonide+Nystatin): serious adverse events	0 of 81	0 of 79	160	NCT01867164

Source Trial comparisons

Papers from its trials0

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

None in this release.

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/EFO_0005757

GET https://conductscience.org/api/diseases/v1/EFO_0005757/drugs

API reference For AI assistants